Zirconium-89 labeled antibodies: general considerations towards radioisotope production and labelling strategies

Kolevska, Katerina and Atanasova, Marija and Cocevska, Maja and Velickovska, Maja and Janevik-Ivanovska, Emilija and Angelovska, Bistra and Ugrinska, Ana (2023) Zirconium-89 labeled antibodies: general considerations towards radioisotope production and labelling strategies. Macedonian pharmaceutical bulletin, 69 (Sup.1). pp. 151-152. ISSN 1857 - 8969

Text Zirconium-89 labeled antibodies.pdf Download (335kB)

Abstract

Radiopharmaceutical preparations based on
zirconium-89 (
89Zr) radioisotope in the last decade have
been increasingly used in preclinical and clinical studies
for visualisation by positron emission tomography (PET).
There are literature data on 89Zr labelling of nanoparticles,
proteins, peptides and cells, but antibody labelling is the
main application of this radioisotope. As a long-lived
radiometal, with a half-life of 78.4 h, zirconium-89 is
suitable for visualising slow biological processes, such as
antibody biodistribution (immuno-PET). 89Zr-immuno PET imaging is a promising technique for predicting the
efficacy of radioimmunotherapy and antibody therapies,
imaging target expression, detecting target-expressing
tumours, and monitoring anti-cancer chemotherapies.
According to ClinicalTrials.gov, there are more than 120
clinical studies, of which already completed studies
involve more than 20 antibodies labelled with 89Zr. The
most common antibodies used in these clinical trials are
bevacizumab, trastuzumab, IAB2M, cetuximab,
pembrolizumab, J591, panitumumab, girentuximab,
pertuzumab etc. The purpose of this paper is to present the
most common methods of producing zirconium-89
radioisotope and antibody labelling strategies.

Item Type:	Article
Subjects:	Medical and Health Sciences > Other medical sciences
Divisions:	Faculty of Medical Science
Depositing User:	Maja Cocevska
Date Deposited:	27 Jun 2024 10:57
Last Modified:	27 Jun 2024 10:57
URI:	https://eprints.ugd.edu.mk/id/eprint/34348

Actions (login required)

View Item